Pharming Group N.V.
NASDAQ:PHARBiotechnology
+$0.28 today
- Market cap
- $882.43M
- Beta
- 0.10
- P/E (TTM)
- 77.0
- EPS (TTM)
- $0.02
Volume 0.01M
Average 0.01M
PHAR Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Pharming Group N.V.NASDAQ: PHAR
Operating Margin · Q1 FY2026 · quarter ended Mar 2026
Operating margin widens to -7.3%
Operating margin was -7.3% in Q1 FY2026, up 1.6 pp from a year earlier. On a trailing-twelve-month basis it was 6.3%, up 6.1 pp year over year. Over 3 fiscal years it narrowed by 3.3 pp.
Context
- Operating margin widened in 1 of the last 3 fiscal years.
What to watch
Whether operating margin reaches the consensus estimate from 3 analysts of 11.2% for the fiscal year ending Dec 2026, up from 5.5% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -7.3%-9.2 pp QoQ
- Last fiscal yearDec 2025
- 5.5%+8.4 pp YoY
- LTMMar 2026
- 6.3%+6.1 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +1.6 pp | -2.6 pp | -4.2 pp |
| 1 year | +8.4 pp | +5.7 pp | -2.8 pp |
| 3 years | -3.3 pp | +11.4 pp | +14.7 pp |
| 5 years | +4.2 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 5.5%
- Year-over-year change
- +8.4pp
| Period | Period end | Operating Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.5% | +8.4pp |
| FY2024 | 2024-12-31 | -2.9% | -0.7pp |
| FY2023 | 2023-12-31 | -2.2% | -11.1pp |
| FY2022 | 2022-12-31 | 8.9% | +2.0pp |
| FY2021 | 2021-12-31 | 6.8% | — |
Operating Margin vs competitors
How PHAR compares with its peers on the latest reported figures
- PHAR's LTM Mar 2026 operating margin of 6.3% is the highest of the 8 companies compared; the peer median is -345.5%.
- Its year-over-year change of +6.1 pp is the 2nd highest of 7, against a peer median of -36.6 pp.
- Over three fiscal years its change of -3.3 pp compares with a peer median of +93.8 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 6.3% | +6.1 pp | -3.3 pp | |
| LTM Sep 2026 | -8.0% | -27.9 pp | +8.9 pp | |
| LTM Jun 2026 | -33.3% | -43.0 pp | +93.8 pp | |
| LTM Sep 2026 | -58.9% | -30.2 pp | +29.4 pp | |
| LTM Mar 2026 | -345.5% | -170.5 pp | +1537.1 pp | |
| LTM Mar 2026 | -577.5% | -597.5 pp | +830.1 pp | |
| LTM Mar 2026 | -636.6% | +550.8 pp | +227.4 pp | |
| LTM Mar 2026 | -9396.6% | — | -15774.1 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding PHAR) | -345.5% | -36.6 pp | +93.8 pp | |
Competitors are the stored peer set for PHAR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 225.46M | 205.62M | 245.32M | 307.75M | 377.18M |
| Cost of Revenue | 23.97M | 17.56M | 25.21M | 36.66M | 45.63M |
| Gross Profit | 201.49M | 188.06M | 220.1M | 271.09M | 331.56M |
| Gross Margin | 89.4% | 91.5% | 89.7% | 88.1% | 87.9% |
| Research & Development | 79.78M | 52.53M | 68.91M | 86.1M | 98.08M |
| Selling, General & Admin | 54.56M | 68.85M | 87.5M | 102.74M | 117.44M |
| Operating Expenses | 186.12M | 169.83M | 225.49M | 280.02M | 309.75M |
| Depreciation & Amortization | 22.23M | 13.19M | 15.93M | 16.64M | 10.76M |
| EBITDA | 55.3M | 33.53M | 9.88M | 16.89M | 31.7M |
| EBITDA Margin | 24.5% | 16.3% | 4.0% | 5.5% | 8.4% |
| Operating Income | 15.37M | 18.23M | (5.39M) | (8.93M) | 20.88M |
| Operating Margin | 6.8% | 8.9% | -2.2% | -2.9% | 5.5% |
| Interest Income | 59.99K | 85K | 3.53M | 5.92M | 2.56M |
| Interest Expense | 7M | 5.36M | 5.96M | 9.05M | 21.31M |
| Other Income / Expenses | 10.79M | (3.25M) | (6.63M) | 133.58K | (8.03M) |
| Income Before Tax | 26.16M | 14.99M | (12.01M) | (8.79M) | 12.88M |
| Pre-Tax Margin | 11.6% | 7.3% | -4.9% | -2.9% | 3.4% |
| Income Tax Expense | 8.03M | 1.31M | (1.46M) | 3.47M | 10.34M |
| Net Income | 18.13M | 13.67M | (10.55M) | (12.26M) | 2.86M |
| Net Margin | 8.0% | 6.7% | -4.3% | -4.0% | 0.8% |
| EPS (Basic) | 0.23 | 0.17 | (0.14) | (0.18) | 0.04 |
| EPS (Diluted) | 0.21 | 0.16 | (0.14) | (0.18) | 0.04 |
| Weighted Avg Shares | 87.64M | 82.54M | 65.7M | 68.92M | 71.32M |
| Weighted Avg Shares (Diluted) | 87.64M | 84.28M | 65.7M | 68.92M | 71.32M |
Pharming Group N.V.
NASDAQ:PHAR
Intrinsic Alpha fair value
Locked
Current Price
$12.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.